Within TME, they can impair immune clearance of tumour cells through secretion of immunosuppressive cytokines and expression of co-inhibitory cell surface molecules (e.g., CTLA-4) and have been demonstrated to be associated with tumour progression and reduced survival in several cancers [95]. The gene discussed is CTLA4; the disease is neoplasm.